Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.
Aim(s): The aim of this retrospective study was to examine safety and treatment compliance in CAPTEM-treated pts with diverse advanced NETs.
Materials and methods: Pts were treated with CAP 750mg/m2 BD (day1-14) and TEM 200mg/m2 OD (day10-14) orally in a 28 day cycle up to a maximum of 6 cycles. Alive pts completed retrospectively a treatment satisfaction survey.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Georgios Papaxoinis
To read results and conclusion, please login ...
Further abstracts you may be interested in